MPM BioImpact
MPM BioImpact is a world-leading biotechnology investment firm with over 30 years of experience in creating and investing in innovative companies. The firm focuses on delivering transformative therapies to patients by investing in both private and public biotech companies. MPM BioImpact is dedicated to impact investing, managing over $3 billion in assets across early-stage venture funds, private/public impact funds, and a public equities fund. The firm is known for its role as a company creator, leveraging deep domain expertise in research and development, clinical strategy, and commercialization to build successful biotech companies.
MPM BioImpact
399 Boylston Street, Suite 1100, Boston, MA 02116
What We Do
MPM BioImpact specializes in creating biotech companies from the ground up, providing strategic guidance and operational support to develop transformative therapies.
The firm invests in both private and public biotech companies, offering a unique longitudinal view of drug development across the industry.
MPM BioImpact provides strategic guidance and mentorship to its portfolio companies, leveraging its extensive experience in the biotech sector.
The firm offers its portfolio companies access to a wide network of industry experts and resources to support their growth and development.
Fund Size
Industry Focus
Portfolio
Orna Therapeutics focuses on developing a new class of circular RNA medicines. It has raised $221 million in Series B financing and has a strategic partnership with Merck.
#Biotechnology
Aktis Oncology is pioneering miniprotein actinium-conjugates for cancer treatment and has raised $175 million in Series B financing.
#Biotechnology
ElevateBio focuses on cell, gene, and RNA therapies and has raised $401 million in Series D financing.
#Biotechnology
NextPoint Therapeutics is developing first-in-class precision therapies for cancer and has raised $80 million in Series B financing.
#Biotechnology
Key People
Chairman
Chief Scientific Officer
Chief Medical Officer
Co-Founder